Kaplan–Meier survival analysis further supported TIGD1 as a risk factor in esophageal carcinoma, LIHC, KIRC, and sarcoma, but indicated a protective role in bladder urothelial carcinoma, cervical squamous cell carcinoma and endocervical adenocarcinoma, ovarian cancer, stomach adenocarcinoma, and testicular germ cell tumors (Figure 5b). Here, TIGD1 is linked to bladder transitional cell carcinoma.